NOVN.SW Novartis (SIX) pre-market 30 Jan 2026: CHF114.20 ahead of earnings call
We start pre-market with the main fact: NOVN.SW stock trades at CHF114.20 on the SIX in Switzerland as investors position ahead of the 4 February 2026 earnings release. Volume early is 2,923,344 shares, near the 50-day average of 2,922,290. The upcoming report will focus on Innovative Medicines sales, Sandoz recovery, and guidance items that can move price and sentiment.
NOVN.SW stock snapshot and trading facts
Novartis AG (NOVN.SW) opened pre-market at CHF115.64 and shows a day range of CHF113.76–CHF115.76. The shares trade on the SIX in Switzerland with market cap near CHF219.28B and 1,918,792,119 shares outstanding. Key quoted metrics: EPS CHF5.69, P/E 20.08, and 50-day average price CHF109.61.
Earnings spotlight: calendar and likely catalysts
Novartis reports results on 4 February 2026, with the company set to detail revenue, margin trends, and guidance for 2026. Analysts will watch momentum in innovative medicines, Sandoz profit progression, and updates on inclisiran partnerships. A surprise on margins or guidance will likely drive intraday volatility.
Fundamentals and valuation: what the numbers show
Novartis shows solid cash generation with free cash flow per share CHF9.39 and a free cash flow yield 6.39%. The shares trade at P/E 20.08 and P/B 6.56, above healthcare peers on price-to-book. Leverage sits at debt/equity 0.72, and dividend per share is CHF4.57, a 3.06% yield, supporting an income case for long-term investors.
Technical setup and short-term momentum for NOVN.SW stock
Momentum indicators are bullish: RSI 74.23, MACD positive, and price sits above the 50-day (CHF109.61) and 200-day (CHF100.82) averages. Short-term signals point to overbought conditions, suggesting earnings-driven pullbacks are possible despite an upward trend.
Meyka AI grade and NOVN.SW stock forecast
Meyka AI rates NOVN.SW with a score of 74.44 out of 100 — Grade B+, suggestion BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects monthly CHF123.14 and yearly CHF108.32, with model-based caveats noted below.
Risks and opportunities tied to the earnings report
Opportunity: stronger-than-expected Innovatives sales or clearer Sandoz margin recovery could lift sentiment and the stock. Risk: weaker EPS or conservative guidance will likely trigger a near-term sell-off, given heavy positioning and overbought technicals.
Final Thoughts
Key takeaways for NOVN.SW stock: the pre-market price of CHF114.20 positions Novartis ahead of the 4 Feb 2026 earnings release, where revenue mix and guidance will matter most. Fundamentals support a steady case: EPS CHF5.69, P/E 20.08, and free cash flow per share CHF9.39. Meyka AI’s forecast model projects monthly CHF123.14, implying an upside of +7.83% versus the current price. The model’s yearly projection is CHF108.32, implying -5.14% downside. Our practical scenario price targets: conservative CHF100.00, base CHF120.00, bull CHF135.00. These targets reflect valuation, cash flow strength, and sector peers. Forecasts are model-based projections and not guarantees. For traders, expect earnings-driven volatility; for longer-term holders, monitor guidance and free cash flow conversion as the main outcome metrics. Meyka AI provides this as an AI-powered market analysis platform point of reference, not investment advice.
FAQs
When does Novartis report earnings?
Novartis (NOVN.SW) is scheduled to report earnings on 4 February 2026. Investors should watch revenue mix, Sandoz margins, and management guidance for 2026.
What is the current valuation of NOVN.SW stock?
At CHF114.20, Novartis trades at P/E 20.08 and P/B 6.56. Free cash flow per share is CHF9.39, and dividend yield is 3.06%, indicating a strong cash profile but a premium book valuation.
What does Meyka AI forecast for NOVN.SW stock?
Meyka AI’s forecast model projects monthly CHF123.14 and yearly CHF108.32 for NOVN.SW stock. Monthly implies +7.83% upside versus current price. Forecasts are model projections, not guarantees.
What are the main risks ahead of the earnings release?
Main risks are weaker-than-expected EPS, disappointing Sandoz recovery, or cautious guidance. Overbought technicals raise the chance of an earnings-driven pullback.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
